

EVOTEC EXPANDS beLAB1407 BRIDGE PARTNERSHIP WITH BRISTOL MYERS SQUIBB TO INCLUDE 3 NEW UNIVERSITY PARTNERS

- ▶ *beLAB1407 WAS CREATED BY EVOTEC AND BRISTOL MYERS SQUIBB TO TRANSLATE INNOVATIONS FROM LEADING ACADEMIC INSTITUTIONS IN THE UK*
- ▶ *EVOTEC'S UNIQUE MULTIMODALITY PLATFORM WILL NOW BE MADE AVAILABLE TO THE UNIVERSITY OF BRISTOL, UNIVERSITY OF GLASGOW AND QUEEN MARY UNIVERSITY OF LONDON TO VALIDATE FIRST-IN-CLASS CONCEPTS*

Hamburg, Germany 22 November 2023:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the expansion of its \$20 million beLAB1407 BRIDGE partnership with Bristol Myers Squibb to include the Universities of Bristol and Glasgow as well as Queen Mary University of London.

beLAB1407 was launched in 2021 with the Universities of Birmingham, Dundee, Edinburgh and Nottingham as founding partners to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas. Under the expanded beLAB1407 agreement, the Universities of Bristol and Glasgow as well as Queen Mary University of London will benefit from access to funding, expertise and drug discovery and development platforms spanning multiple disease areas and modalities.

beLAB1407 is one of Evotec's global portfolio of BRIDGE partnerships. BRIDGEs provide an integrated fund and award framework to validate exciting academic projects in collaboration with Pharma companies and/or venture investors to develop first-in-class therapies that can form the basis of new biotech companies or out-licensing transactions.

Dr Thomas Hanke, EVP Head of Academic Partnerships at Evotec, commented: "UK universities are sources of proven high-quality research to elucidate new therapeutic targets, platforms and candidates. Each of our new university partners brings an impressive biomedical research track record to the table and -through beLAB1407- we look forward to supporting them building strong

For further information, please contact the Corporate Communications Team:

Hinnerk Rohwedder, Director of Global Corporate Communications, hinnerk.rohwedder@evotec.com;

Gabriele Hansen, SVP Head of Global Corporate Communications, gabriele.hansen@evotec.com, www.evotec.com

translational foundations for projects with the potential to yield first-in-class therapies that can positively impact patient care.”

Professor Jeremy M. Tavaré, Pro Vice-Chancellor and Executive Dean, Faculty of Health and Life Sciences at the University of Bristol said:

“Bristol is a leading University in terms of the depth and quality of its biomedical research and the number of new ventures that are formed to accelerate its translation towards patient benefit. We are excited to be joining the beLAB1047 consortium which will enable us to access world-leading capabilities to support and accelerate the development of potential new therapies and better position these for onward investment.”

Uzma Khan, Vice Principal of Economic Development and Innovation at the University of Glasgow said:

“The University of Glasgow is delighted to be joining the beLAB1407 consortium which will significantly enhance our ability to generate positive impact in the context of drug discovery and on patient care. This initiative is a hugely important addition to our innovation eco-system in Scotland for biomedical research. It will provide our researchers with access to valuable pharmaceutical industry expertise along with resources that can support the translation of disease-related scientific discoveries into value propositions that can attract investment for further pre-clinical and clinical development.”

Dr Phil Clare, Chief Executive Officer, Queen Mary Innovation,

commented: “We’re delighted to be joining this exciting partnership, sharing expertise to discover new drugs and bringing them to patients through creating spinouts. Queen Mary University of London is home to one of Britain’s biggest research and teaching hospitals, making us an ideal partner in turning academic research into real world impact.”

About Evotec’s BRIDGE model: Partnering to accelerate innovation

Evotec has created a new paradigm to translate early-stage academic research to drug discovery and development called “BRIDGE” (Biomedical Research, Innovation & Development Generation Efficiency), an integrated accelerator-by-award framework to tap into academic science to accelerate the formation of spin-out companies and generate collaborations with Pharma and biotech. Through these efforts, Evotec has defined a new formula for fast-track early-stage drug discovery. Since the launch of the BRIDGE model in 2016, Evotec has formed and funded a growing number of strategic collaborations, such as LAB282, LAB150, Danube Labs, beLAB2122, beLAB1407, LAB eN², 65LAB and Pre-Amp, as well as investments into start-up

studios focused on academic innovation such as Autobahn-Labs, Argobio and Extend.

Please visit www.evotec.com/en/innovate/bridges to learn more about Evotec's BRIDGES.

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.